Search Results
Feb 07, 2026, 23:32 ET ANKÜNDIGUNG DER ANHÖRUNG ZUR GENEHMIGUNG DES VERGLEICHS - KURZFASSUNG - WAYLAND GROUP CORP., SCOTT LANGILLE, GERHARD MÜLLER, PAUL PATHAK, ERIC SILVER, MICHAEL STEIN, JOHN DOES 1-3, CANACCORD GENUITY CORP. UND RF SECURITIES CLEARING LP (FRÜHER BEKANNT ALS GMP SECURITIES L.P.) - WERTPAPIER-SAMMELKLAGEN
Gerhard Muller, Paul Pathak, Eric Silver, Michael Stein und John Does 1-3, Court File No. CV-22-00687490-00CP (die „Stajic-Klage"); und (iii) Michaël Bordeleau-Tassile v. Canaccord Genuity Corp, und GMP Securities L.P., Court File No. CV-23-00693650-00CP (die „Bordeleau-Tassile-Klage"
More news about: Berger Montague (Canada) PC
Feb 07, 2026, 10:18 ET NOTICE OF SETTLEMENT APPROVAL HEARING - SHORT FORM - WAYLAND GROUP CORP., SCOTT LANGILLE, GERHARD MÜLLER, PAUL PATHAK, ERIC SILVER, MICHAEL STEIN, JOHN DOES 1-3, CANACCORD GENUITY CORP., AND RF SECURITIES CLEARING LP (FORMERLY KNOWN AS GMP SECURITIES L.P.) - SECURITIES CLASS ACTIONS
Gerhard Muller, Paul Pathak, Eric Silver, Michael Stein and John Does 1-3, Court File No. CV-22-00687490-00CP (the "Stajic Action"); and (iii) Michaël Bordeleau-Tassile v. Canaccord Genuity Corp., and GMP Securities L.P., Court File No. CV-23-00693650-00CP (the "Bordeleau-Tassile
More news about: Berger Montague (Canada) PC
Feb 06, 2026, 22:22 ET Coupang Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuits Against Coupang, Inc. - CPNG
information for nearly six months without being detected; (ii) this subjected the Company to a materially heightened risk of regulatory and legal scrutiny; (iii) when defendants became aware that the Company had been subjected to this data breach, they did not report it in a current report filing in compliance
More news about: ClaimsFiler
Feb 06, 2026, 22:20 ET CoreWeave Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against CoreWeave, Inc. - CRWV
severity of the risk that its reliance on a single third-party data center supplier created for its ability to meet customer demand for its services; (iii) the foregoing was reasonably likely to have a material negative impact on the Company's revenue; and (iv) as a result, CoreWeave's public statements
More news about: ClaimsFiler
Feb 06, 2026, 22:16 ET Ultragenyx Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against Ultragenyx Pharmaceutical Inc. - RARE
Company announced the "results from the Phase 3 Orbit and Cosmic studies for setrusumab (UX143) in Osteogenesis Imperfecta" disclosing that both its Phase III Orbit and Cosmic studies failed to demonstrate that setrusumab triggered a statistically significant reduction in annualized fracture rates for patients
More news about: ClaimsFiler
Feb 06, 2026, 18:35 ET MONTGOMERY CAPITAL PARTNERS IV, LP TO AUCTION THE PERSONAL PROPERTY OF ROSE DE NUIT, LLC AND JKY GROUP, LLC VIA PUBLIC SALE
liability company (collectively, "Borrower"), including, without limitation, (i) inventory ("Inventory"), (ii) accounts receivable ("Accounts Receivable"), (iii) certain machinery and equipment owned by Borrower (collectively, the "FF&E"), (iv) the following trademarks owned by Borrower: (1) "SPHINX BEAUTY.
More news about: Montgomery Capital Advisers, LLC
Feb 06, 2026, 16:30 ET INVESTOR ALERT: CoreWeave, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
that CoreWeave's reliance on a single third-party data center supplier presented for CoreWeave's ability to meet customer demand for its services; and (iii) the foregoing was reasonably likely to have a material negative impact on CoreWeave's revenue.The CoreWeave class action lawsuit alleges
More news about: Robbins Geller Rudman & Dowd LLP
Feb 06, 2026, 16:20 ET INVESTOR ALERT: Ardent Health, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit, Robbins Geller Rudman & Dowd LLP Announces - ARDT
allowed Ardent Health to report higher amounts of accounts receivable during the Class Period, and delay recognizing losses on uncollectable accounts; (iii) consequently, Ardent Health's reported financial position was materially false and misleading; (iv) Ardent Health did not maintain professional malpractice
More news about: Robbins Geller Rudman & Dowd LLP
Feb 06, 2026, 16:10 ET Axcelis Stockholders Approve Merger with Veeco
statements pertaining to: (i) future industry demand for semiconductors and wafer fabrication equipment; (ii) future development of regulatory landscape; (iii) Axcelis' or Veeco's market position for the future; (iv) forecasts of financial measures for future periods; (v) long-term financial targets and underlying
More news about: Axcelis Technologies, Inc.
Feb 06, 2026, 13:56 ET American Trailer Manufacturers Coalition Commends ITC for Affirmative Preliminary Injury Determination in AD/CVD Case
Robert E. DeFrancesco, III, counsel to the American Trailer Manufacturers
More news about: American Trailer Manufacturers Coalition
Feb 06, 2026, 13:53 ET John McNichols, Former Partner of Williams & Connolly LLP, Joins Torridon Law PLLC
News, having authored more than twenty published articles. Before beginning private practice, Mr. McNichols clerked for a year for Judge T. S. Ellis III of the U.S. District Court for the Eastern District of Virginia.Mr. McNichols is also a former non-commissioned officer of the U.S. Army Special
More news about: Torridon Law PLLC
Feb 06, 2026, 10:57 ET Sonata Software consolidated PAT (before exceptional item) grew by 6.1% QoQ and 21.4 % YoY.
compliance. We enable our clients to leverage AI in three different ways: i) driving efficiencies, ii) driving higher consumer experience/modern sales, and iii) driving innovative business models. We have launched bleeding edge Agentic AI offering – AgentBridge – that enables enterprises to usher in the era
More news about: Sonata Software
Feb 06, 2026, 10:49 ET Sonata Software consolidated PAT (before exceptional item) grew by 6.1% QoQ and 21.4 % YoY.
compliance. We enable our clients to leverage AI in three different ways: i) driving efficiencies, ii) driving higher consumer experience/modern sales, and iii) driving innovative business models. We have launched bleeding edge Agentic AI offering – AgentBridge – that enables enterprises to usher in the era
More news about: Sonata Software
Feb 06, 2026, 10:42 ET NAPCO Security Technologies to Participate in Barclay's 43rd Annual Industrial Select Conference and Citi's 2026 Global Industrial Tech & Mobility Conference
the Company undertakes no duty to update such information, except as required under applicable law. Contact: Francis J. Okoniewski IIIVice President of Investor Relations NAPCO Security Technologies, Inc. 800-645-9445 x 374 Mobile: 516-404-3597 fokoniewski
More news about: NAPCO Security Technologies, Inc.
Feb 06, 2026, 10:40 ET Hexaware Named a Top 15 Sourcing Standout by ISG
ISG (Nasdaq: III) is a global AI-centered technology research and advisory firm. A trusted partner to more than 900 clients, including 75 of the world's top 100
More news about: Hexaware Technologies Ltd.
Feb 06, 2026, 10:00 ET Folger Theatre Announces Cast and Creative Team for William Shakespeare's "As You Like It"
a full heart and restless soul that I eagerly return to the Folger stage, having made my professional directing debut here in 1995 with Richard III, and then followed up by a joyous return with a DC Caribbean community-inspired Much Ado About Nothing," stated Douglas. "It is now my honor
More news about: Folger Shakespeare Library
Feb 06, 2026, 08:49 ET RARE Investor Alert: Faruqi & Faruqi, LLP Reminds Ultragenyx (RARE) Investors of Securities Class Action Deadline on April 6, 2026
Ultragenyx' Phase III Orbit study would fail to achieve a statistically significant reduction in annualized fracture rate ("AFR"), such that the second interim analysis could be performed and presented to the investing public; and (ii) in truth, Ultragenyx' optimism in the Phase III Orbit study's results
More news about: Faruqi & Faruqi, LLP
Feb 06, 2026, 08:49 ET PLUG Investor Alert: Faruqi & Faruqi, LLP Reminds Plug Power Investors of Securities Class Action Deadline on April 3, 2026
facilities necessary to receive those funds; (ii) as such, Plug Power was likely to pivot toward more modest projects with less commercial upside; and (iii) as a result, the Company's public statements were materially false and misleading at all relevant times.The court-appointed lead plaintiff is
More news about: Faruqi & Faruqi, LLP
Feb 06, 2026, 08:00 ET WHITE MOUNTAINS REPORTS FOURTH QUARTER RESULTS
and unrealized investment gains (losses) on Kudu's revenue and earnings participation contracts, (ii) non-cash equity-based compensation expense and (iii) transaction expenses. A description of each item follows:Net realized
More news about: White Mountains Insurance Group, Ltd.
Feb 06, 2026, 06:00 ET Hyperscale Data Announces Estimated Total Assets and Net Assets per Share of $0.90 and $0.35, Respectively, as of January 31, 2026
despite significant volatility in the recent weeks and are extremely confident in the long-term nature of Bitcoin," stated Milton "Todd" Ault III, Executive Chairman of Hyperscale Data. "When we purchase Bitcoin, we purchase it through a long-term lens of owning it for more than five
More news about: Hyperscale Data Inc.
Feb 06, 2026, 04:00 ET Kelun-Biotech Announces Fourth Indication for Sacituzumab Tirumotecan (sac-TMT) Approved by NMPA in HR+/HER2- Breast Cancer
The approval is based on the positive results from the Phase III OptiTROP-Breast02 study which was selected as a Late-Breaking Abstract (LBA) and presented as an oral report at the 2025 European Society for Medical
More news about: Kelun-biotech
Feb 06, 2026, 02:00 ET RARE Stockholder Alert: Robbins LLP Reminds Investors of the Class Action Against Ultragenyx Pharmaceutical Inc.
Inc. (RARE) Misled Investors Regarding Phase III Orbit and Cosmic Studies for SetrusumabAccording to the complaint, during the class period, defendants provided investors with material information concerning Ultragenyx's expected results for its Phase III Orbit and Cosmic Studies, which tested setrusumab
More news about: Robbins LLP
Feb 05, 2026, 21:26 ET Akeso Receives Fifth Breakthrough Therapy Designation from NMPA for Ivonescimab in First-Line Treatment of Advanced Biliary Tract Cancer
ivonescimab's broad clinical potential across multiple high unmet need tumor types.A randomized, controlled, multicenter, registrational Phase III clinical study (AK112-309/HARMONi-GI1) is evaluating ivonescimab plus chemotherapy versus durvalumab (a PD-L1 inhibitor) plus chemotherapy for first-line
More news about: Akeso, Inc.
Feb 05, 2026, 19:36 ET Eisai und Henlius schließen exklusive Lizenzvereinbarung für den Anti-PD-1-Antikörper Serplulimab in Japan ab
Grundlage der Ergebnisse der Überbrückungsstudie und der Phase-III-Daten, die die Zulassungen in China und Europa unterstützen, im Geschäftsjahr 2026 einen Zulassungsantrag einzureichen. Darüber hinaus läuft eine multinationale klinische Phase-III-Studie zur Behandlung von metastasierendem Dickdarmkrebs
More news about: Henlius
Feb 05, 2026, 19:36 ET Eisai et Henlius concluent un accord de licence commerciale exclusive pour l'anticorps anti-PD-1 serplulimab au Japon
cours de l'exercice 2026 fondée sur les résultats de l'étude de liaison et des données de phase III soutenant les approbations en Chine et en Europe. En outre, un essai clinique multinational de phase III pour le cancer colorectal métastatique non MSI-H est en cours, et un développement ultérieur dans
More news about: Henlius